PET-CT scans combine structural and functional imaging to detect diseases early. This technology improves diagnosis accuracy ...

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

On Thursday this week, the Aga Khan University Hospital sent a statement announcing it had also conducted the treatment.This therapy uses a radioactive substance, Lutetium-177, to target and kill ...

The report provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally.

Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. Learn how it can help with prostate cancer.

PSMA-PET scans detect metastatic disease in 46% of patients with high-risk nonmetastatic hormone-sensitive prostate cancer, revealing understaging by conventional imaging.

Video: Integrating PSMA-PET Scans into the Management of Advanced Prostate Cancer —Joseph Renzulli, MD, Associate Professor of Urology at Yale School of Medicine, discusses how the scope of the ...